Lukas Biomedical Inc. (TPEX:6814)
Taiwan · Delayed Price · Currency is TWD 19.85
-1.65 (-7.67%)
Aug 26, 2026, 1:51 PM CST
Lukas Biomedical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 170.01 | 179.49 | 189.83 | 231.83 | 184.79 | 157.62 | |
Revenue Growth | -5.72% | -5.44% | -18.12% | 25.46% | 17.24% | -13.11% |
Cost of Revenue | 68.2 | 71.63 | 76.71 | 97.94 | 86.88 | 61.56 |
Gross Profit | 101.81 | 107.87 | 113.12 | 133.89 | 97.91 | 96.06 |
Selling, General & Admin | 107.8 | 106.24 | 110.32 | 100.12 | 90.55 | 85.33 |
Research & Development | 81.17 | 82.78 | 94.73 | 77.33 | 55.92 | 54.98 |
Operating Expenses | 188.98 | 189.03 | 205.25 | 177.45 | 146.37 | 139.13 |
Operating Income | -87.17 | -81.16 | -92.14 | -43.56 | -48.47 | -43.06 |
Interest Expense | -3.9 | -3.21 | -3.04 | -3.07 | -2.92 | -4.42 |
Interest & Investment Income | 0.26 | 0.26 | 0.46 | 0.09 | 0.07 | 0.04 |
Currency Exchange Gain (Loss) | -0.07 | -0.07 | -0.01 | -1 | 1 | -0.14 |
Other Non Operating Income (Expenses) | 0.66 | 0.4 | 0.25 | 0.47 | -0.83 | 0.71 |
EBT Excluding Unusual Items | -90.22 | -83.78 | -94.47 | -47.07 | -51.14 | -46.86 |
Gain (Loss) on Sale of Assets | 0.02 | 0.02 | - | -0.47 | 1.02 | -1.21 |
Asset Writedown | 0.03 | - | - | - | - | - |
Other Unusual Items | 0 | 0 | - | 0.26 | 0.2 | 0.24 |
Pretax Income | -90.18 | -83.76 | -94.47 | -47.28 | -49.92 | -47.83 |
Income Tax Expense | 1.87 | 1.87 | -0.1 | 0.08 | 0.15 | 1.66 |
Earnings From Continuing Operations | -92.05 | -85.63 | -94.38 | -47.35 | -50.07 | -49.49 |
Net Income | -92.05 | -85.63 | -94.38 | -47.35 | -50.07 | -49.49 |
Net Income to Common | -92.05 | -85.63 | -94.38 | -47.35 | -50.07 | -49.49 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 42 | 42 | 40 | 37 | 37 | 33 |
Shares Outstanding (Diluted) | 42 | 42 | 40 | 37 | 37 | 33 |
Shares Change | 0.38% | 5.80% | 7.34% | 0.27% | 11.87% | - |
EPS (Basic) | -2.19 | -2.05 | -2.38 | -1.28 | -1.36 | -1.51 |
EPS (Diluted) | -2.19 | -2.05 | -2.38 | -1.28 | -1.36 | -1.51 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -67.87 | -69.64 | -77.35 | -14.41 | -10.41 | -26.18 |
Free Cash Flow Per Share | -1.62 | -1.66 | -1.95 | -0.39 | -0.28 | -0.80 |
Gross Margin | 59.88% | 60.09% | 59.59% | 57.75% | 52.98% | 60.95% |
Operating Margin | -51.27% | -45.22% | -48.54% | -18.79% | -26.23% | -27.32% |
Profit Margin | -54.14% | -47.71% | -49.72% | -20.42% | -27.10% | -31.40% |
Free Cash Flow Margin | -39.92% | -38.80% | -40.75% | -6.21% | -5.63% | -16.61% |
EBITDA | -76.22 | -69.81 | -77.85 | -26.3 | -25.63 | -18.68 |
EBITDA Margin | -44.83% | -38.89% | -41.01% | -11.34% | -13.87% | -11.85% |
D&A For EBITDA | 10.96 | 11.35 | 14.28 | 17.26 | 22.83 | 24.38 |
EBIT | -87.17 | -81.16 | -92.14 | -43.56 | -48.47 | -43.06 |
EBIT Margin | -51.27% | -45.22% | -48.54% | -18.79% | -26.23% | -27.32% |
Advertising Expenses | - | 36.73 | - | - | - | - |